Garry Nolan is a prominent immunologist and profes
Post# of 157833
(Total Views: 806)
Posted On: 07/27/2025 10:12:45 PM
Garry Nolan is a prominent immunologist and professor at Stanford University. After seeing him speak of his HIV and Coronavirus skill stack, and recent build of devices to improve atomic vision by a factor of 10, primarily for cancer research, take a read below, and watch an entertaining interview of him first explaining himself:
https://www.youtube.com/watch?v=HxVVz2Jorzk
if not an ally of leronlimab, someone here who knows him needs to suggest he become an ally.
Garry Nolan is a prominent immunologist and professor at Stanford University, known for his work in biotechnology and tool development, particularly in the field of single-cell analysis using technologies like CyTOF and MIBI.
While Nolan's research focuses on immunology, cancer, and inflammation, there is no direct evidence to link him specifically with research on the investigational drug leronlimab. Leronlimab is a monoclonal antibody being developed for conditions like HIV infection and triple-negative breast cancer. It works by targeting the CCR5 receptor on T lymphocytes, which plays a role in HIV infection, tumor metastasis, and immune cell trafficking.
It is important to note that CytoDyn, the company developing leronlimab, has faced controversy, including criticisms from the FDA regarding their presentation of data in trials for COVID-19. The FDA concluded that the data did not support the clinical benefit of leronlimab for treating COVID-19, according to the U.S. Food and Drug Administration (.gov).
Further research would be needed to clarify if there is any indirect connection between Garry Nolan and leronlimab, perhaps through his work on the CCR5 receptor or related areas of immunology. However, based on the provided search results, his direct involvement in leronlimab research is not evident.
GLTL
https://www.youtube.com/watch?v=HxVVz2Jorzk
if not an ally of leronlimab, someone here who knows him needs to suggest he become an ally.
Garry Nolan is a prominent immunologist and professor at Stanford University, known for his work in biotechnology and tool development, particularly in the field of single-cell analysis using technologies like CyTOF and MIBI.
While Nolan's research focuses on immunology, cancer, and inflammation, there is no direct evidence to link him specifically with research on the investigational drug leronlimab. Leronlimab is a monoclonal antibody being developed for conditions like HIV infection and triple-negative breast cancer. It works by targeting the CCR5 receptor on T lymphocytes, which plays a role in HIV infection, tumor metastasis, and immune cell trafficking.
It is important to note that CytoDyn, the company developing leronlimab, has faced controversy, including criticisms from the FDA regarding their presentation of data in trials for COVID-19. The FDA concluded that the data did not support the clinical benefit of leronlimab for treating COVID-19, according to the U.S. Food and Drug Administration (.gov).
Further research would be needed to clarify if there is any indirect connection between Garry Nolan and leronlimab, perhaps through his work on the CCR5 receptor or related areas of immunology. However, based on the provided search results, his direct involvement in leronlimab research is not evident.
GLTL
(4)
(0)